PharmaPoint: Healthcare-Associated Gram-Negative Infections-Global Drug Forecast and Market Analysis to 2026
August 2017
379
About the Report
About the Report
PharmaPoint: Healthcare-Associated Gram-Negative Infections-Global Drug Forecast and Market Analysis to 2026
Summary
Healthcare-associated infections (HAIs) are a major threat to patient safety, and place a substantial economic burden on healthcare systems. HAIs occur in hospitalized patients, and are not present at the time of admission. Acute care hospitals are the primary settings for contracting HAIs, with a high concentration occurring within non-nursery wards and intensive care units (ICUs).The most common types of HAIs are related to the use of invasive devices or surgical procedures, and fall into the following infection site categories: catheter-associated urinary tract infection (CAUTI), central line-associated bloodstream infection (CLABSI), hospital-associated pneumonia/ventilator-associated pneumonia (HAP/VAP), and surgical site infection (SSI).
The pharmaceutical industry's battle against Gram-negative bacteria requires ongoing development and novel, innovative approaches for the development of new antibiotics as well as non-antibiotic based approaches. Due to the lack of novel scaffolds being developed over the last few decades and limited investments into antibiotic R&D during this century, the prevalence of resistant Gram-negative bacteria, especially in the hospital setting, has increased significantly; antibiotic resistance is now considered a major threat to the life expectancy of current future generations, including in developed countries. Consequently, industry and governments have recently ramped up their involvement in this space, and several promising antibiotics are now in the late-stage development.
Scope
Overview of HAIs caused by Gram-negative bacteria, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
Topline market revenue from 2016-2026 for HAIs caused by Gram-negative bacteria. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting therapeutics sales in the 7MM.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
Analysis of the current and future market competition in the global therapeutics market for HAIs caused by Gram-negative bacteria. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to-
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global therapeutics market for HAIs caused by Gram-negative bacteria.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the therapeutics market for HAIs caused by Gram-negative bacteria in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Products
Companies
Pfizer
Merck& Co.
The Medicines Company
Shionogi & Co., Ltd.
Tetraphase Pharmaceuticals Inc.
MerLion Pharmaceuticals Pte., Ltd.
Achaogen
Aridis Pharmaceuticals
MedImmune LLC
Allergan
Roche/Genentech
Wockhardt Ltd.
Allecra
Zavante
Table of Contents
Table of Contents
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 Launch of Patented Antibiotics Will Drive Solid Growth Over the Forecast Period
2.2 Pipeline Portfolios Target Highly Resistant Bacteria in Strong Collaborations With Governments
2.3 Drug Portfolios Address Some Unmet Needs, but Some Opportunities Remain With New Foreseeable Challenges
2.4 Companies Must Quickly Adapt to Exploit Opportunities in an Evolving Marketplace
2.5 Novel Antibiotics Are Poised to Drive Growth Despite Entering a Highly Genericized Marketplace
2.6 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Infection Scope and Coverage Overview
4.2 Etiology and Pathophysiology
4.2.1 Etiology
4.2.2 Pathophysiology
4.3 Symptoms
4.4 Prognosis
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.3.1 US
5.3.2 5EU
5.3.3 Japan
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for Suspected HAIs and Gram-Negative HAIs ()
5.5.1 Suspected Incident Cases of Select HAIs
5.5.2 Diagnosed Incident Cases of Select Gram-Negative HAIs
5.5.3 Suspected Incident Cases of Select HAIs by Infection Site
5.5.4 Diagnosed Incident Cases of Select Gram-Negative HAIs by Infection Site
5.5.5 Diagnosed Incident Cases of Select Gram-Negative HAIs by Causative Agent
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis
6 Disease Management
6.1 Diagnosis and Treatment Overview
6.1.1 Diagnosis
6.1.2 Treatment Guidelines
6.1.3 Clinical Practice
6.1.4 Antibiotic Stewardship Programs
6.1.5 Off-Label Use of Antibiotics
6.2 US���.
6.3 5EU��.
6.4 Japan�.
7 Competitive Assessment
7.1 Overview
7.2 Product Profiles-Beta-Lactam Antibiotics
7.2.1 Overview
7.2.2 Fixed Dose Beta-Lactam Combination Drugs
7.2.3 Monobactam antibiotics
7.2.4 Carbapenems
7.2.5 Cephalosporins
7.3 Product Profiles-Fluoroquinolones
7.3.1 Overview
7.3.2 Levofloxacin (numerous brand names)
7.3.3 Ciprofloxacin (numerous brand names)
7.3.4 Moxifloxacin (numerous brand names)
7.4 Product Profiles-Polymixins
7.4.1 Overview
7.4.2 Forecast
7.5 Product Profiles-Aminoglycosides
7.5.1 Overview
7.5.2 Amikacin (numerous brand names)
7.5.3 Gentamicin (numerous brand names)
7.5.4 Tobramycin (numerous brand names)
7.6 Product Profiles-Tetracyclines
7.6.1 Tygacil (tigecycline)
7.7 Product Profiles-Other Antibiotics
8 Unmet Needs Assessment and Opportunity Analysis
8.1 Overview
8.2 Novel Approaches in Drug Development to Address Antibiotic Resistance
8.2.1 Unmet Need
8.2.2 Gap Analysis
8.2.3 Opportunity
8.3 Novel Broad-Spectrum Antibiotics
8.3.1 Unmet Need
8.3.2 Gap Analysis
8.3.3 Opportunity
8.4 Antibiotics Positioned as Pathogen- and Resistance-Specific Therapies
8.4.1 Unmet Need
8.4.2 Gap Analysis
8.4.3 Opportunity
8.5 Expansion of Antimicrobial Stewardship Programs and Awareness
8.5.1 Unmet Need
8.5.2 Gap Analysis
8.5.3 Opportunity
8.6 Financial Incentives for Drug Development and Collaborative Efforts Between Governments/Non-Profits/For-Profits
8.6.1 Unmet Need
8.6.2 Gap Analysis
8.6.3 Opportunity
8.7 Improved Diagnostics for Pathogens and Resistance Patterns
8.7.1 Unmet Need
8.7.2 Gap Analysis
8.7.3 Opportunity
8.8 Improving the Safety and Administration Profile of Antibiotics
8.8.1 Unmet Need
8.8.2 Gap Analysis 0
8.8.3 Opportunity
8.9 Improved Clinical Trial Design
8.9.1 Unmet Need
8.9.2 Gap Analysis
8.9.3 Opportunity
8.10 Improved Prevention of Healthcare-Associated Infections
8.10.1 Unmet Need
8.10.2 Gap Analysis
8.10.3 Opportunity
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
9.2.1 Antibiotics
9.2.2 Antibodies
9.3 Other Drugs in Development
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Profiles-Current Players
10.3.1 Pfizer
10.3.2 Merck& Co.
10.3.3 The Medicines Company
10.3.4 Shionogi & Co., Ltd.
10.3.5 Tetraphase Pharmaceuticals Inc.
10.3.6 MerLion Pharmaceuticals Pte., Ltd.
10.3.7 Achaogen
10.3.8 Aridis Pharmaceuticals
10.3.9 MedImmune LLC
10.3.10 Allergan
10.4 Other Companies With Early-Stage Products
10.4.1 Roche/Genentech
10.4.2 Wockhardt Ltd. 0
10.4.3 Allecra 0
10.4.4 Zavante
11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers-Global Issues
11.2 US���..
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU��.
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.3.1 Forecasting Methodology
12.3.2 Suspected Infections and Diagnosed Patients
12.3.3 Percent Drug-Treated Patients
12.3.4 Antibiotic Resistance Patterns
12.3.5 Drugs Included in Each Therapeutic Class 0
12.3.6 Launch and Patent Expiry Dates 0
12.3.7 General Pricing Assumptions
12.3.8 Individual Drug Assumptions
12.3.9 Generic Erosion
12.3.10 Pricing of Pipeline Agents
12.4 Primary Research-Key Opinion Leaders Interviewed for This Report 0
12.5 Primary Research-Prescriber Survey
12.6 About the Authors
12.6.1 Analyst
12.6.2 Therapy Area Director
12.6.3 Epidemiologist
12.6.4 Reviewers
12.6.5 Global Director of Therapy Analysis and Epidemiology
12.6.6 Global Head and EVP of Healthcare Operations and Strategy
12.7 About GlobalData
12.8 Contact Us
12.9 Disclaimer
List of Figure
1.2 List of Figures
Figure 1: Global Sales for HAI Caused by Gram-Negative Bacteria by Region, 2016 and 2026
Figure 2: Company Portfolio Gap Analysis for HAIs against Gram-Negative Bacteria, 2016-2026
Figure 3: Competitive Assessment of the Late-Stage Pipeline for HAIs against Gram-Negative Bacteria
Figure 4: Illustration Depicting the Key Structural Properties of Gram-Negative Bacteria
Figure 5: Sites of Relevant Gram-Negative HAI Sites
Figure 6: Illustration Depicting the Key Mechanisms of Antibiotic Resistance Observed in Gram-Negative Bacteria
Figure 7: Sources Used to Forecast Suspected Incident Cases of HAIs and Suspected Incident Cases of HAIs by Infection Site
Figure 8: Sources Used and Not Used to Forecast Diagnosed Incident Cases of Gram-Negative HAIs and Diagnosed Incident Cases of Gram-Negative HAIs by Infection Site
Figure 9: Sources Used and Not Used to Forecast Diagnosed Incident Cases of Gram-Negative HAIs by Infection Site by Causative Agent
Figure 10: 7MM, Suspected Incident Cases of Select HAIs by Infection Site, Both Sexes, Ages 18 Years, 2016
Figure 11: 7MM, Diagnosed Incident Cases of Select Gram-Negative HAIs by Infection Site, Both Sexes, Ages 18 Years, 2016
Figure 12: 7MM, Diagnosed Incident Cases of Gram-Negative CAUTI by Causative Agent, Both Sexes, Ages 18 Years, 2016
Figure 13: 7MM, Diagnosed Incident Cases of Gram-Negative CLABSI by Causative Agent, Both Sexes, Ages 18 Years, 2016
Figure 14: 7MM, Diagnosed Incident Cases of Gram-Negative HAP/VAP by Causative Agent, Both Sexes, Ages 18 Years, 2016
Figure 15: 7MM, Diagnosed Incident Cases of Gram-Negative SSI by Causative Agent, Both Sexes, Ages 18 Years, 2016
Figure 16: Empirical and Targeted Treatments of HAIs
Figure 17: Overview of the Unmet Needs for HAIs Caused by Gram-Negative Bacteria
Figure 18: Overview of the Development Pipeline for HAI Against Gram-Negative Bacteria
Figure 19: HAIs Caused by Gram-Negative Bacteria-Phase Pipeline, 2017
Figure 20: Competitive Assessment of Late-Stage Pipeline Agents in HAIs Caused by Gram-Negative Bacteria, 2016-2026 1
Figure 21: Clinical and Commercial Positioning of Aztreonam/Avibactam 1
Figure 22: Clinical and Commercial Positioning of Meropenem/Vaborbactam 200
Figure 23: Clinical and Commercial Positioning of Relebactam/Imipenem/Cilastin 206
Figure 24: Clinical and Commercial Positioning of Cefiderocol 2
Figure 25: Clinical and Commercial Positioning of Eravacycline 2
Figure 26: Clinical and Commercial Positioning of Finafloxacin 2
Figure 27: Clinical and Commercial Positioning of Plazomicin 2
Figure 28: Clinical and Commercial Positioning of Aerumab 2
Figure 29: Clinical and Commercial Positioning of MEDI32
Figure 30: Company Portfolio Gap Analysis in Gram-Negative HAIs, 2016-2026 2
Figure 31: Global Sales for Therapeutics Against HAIs Caused by Gram-Negative Bacteria, by Country/Region, 2016 and 2026 265
Figure 32: Global Sales for Therapeutics Against HAIs Caused by Gram-Negative Bacteria, by Drug Class, 2016 and 2026 2
Figure 33: Sales for Therapeutics Against HAIs Caused by Gram-Negative Bacteria in the US, by Drug Class, 2016 and 2026 2
Figure 34: Sales for Therapeutics Against HAIs Caused by Gram-Negative Bacteria in the 5EU by Drug Class, 2016 and 2026 2
Figure 35: Sales for Therapeutics Against HAIs Caused by Gram-Negative Bacteria in Japan, by Drug Class, 2016 and 2026 2
Figure 36: Patient Flow Used for HAIs with Gram-Negative Bacteria
List of Table
1.1 List of Tables
Table 1: Healthcare-Associated Infections by Gram-Negative Bacteria: Key Metrics in the Seven Major Pharmaceutical Markets
Table 2: Characteristics of Most Important Gram-Negative Bacteria
Table 3: Prevalence of Antibiotic Resistance in Gram-Negative Bacteria Throughout the 7MM
Table 4: Symptoms of HAIs Caused by Gram-Negative Bacteria 4
Table 5: Risk Factors for Diagnosed Incident Cases of HAIs
Table 6: 7MM, Suspected Incident Cases of Select HAIs, Ages 18 Years, Both Sexes, N, Select Years 2016-2026 6
Table 7: 7MM, Diagnosed Incident Cases of Select Gram-Negative HAIs, Ages ?18 Years, Both Sexes, N, Select Years 2016-2026
Table 8: National and International Treatment Guidelines for HAIs
Table 9: HAI Disease Management, Country Profile-US
Table 10: HAI Disease Management, Region Profile-5EU
Table 11: HAI Disease Management, Region Profile-Japan
Table 12: Common Susceptibility Patterns in Gram-Negative Bacteria Isolated From the General Hospital Setting (non-ICU) and ICUs
Table 13: Leading Branded Treatments for HAI, 2016
Table 14: SWOT Analysis of Main Antibiotic Classes for HAIs Caused by Gram-Negative Bacteria
Table 15: Product Profile-Avycaz
Table 16: Efficacy of Avycaz in Patients with cIAIs
Table 17: Efficacy of Avycaz in Patients with cUTIs
Table 18: Safety of Avycaz
Table 19: Product Profile-Zerbaxa
Table 20: Efficacy of Zerbaxa in Patients with cIAIs
Table 21: Efficacy of Zerbaxa in Patients with cUTIs
Table 22: Safety of Zerbaxa
Table 23: Product Profile-Piperacillin/tazobactam
Table 24: Efficacy of Piperacillin/tazobactam in Patients with cIAIs
Table 25: Efficacy of Piperacillin/tazobactam in Patients with HAP
Table 26: Efficacy of Piperacillin/tazobactam in Patients with cUTIs
Table 27: Safety of Piperacillin/Tazobactam
Table 28: Product Profile-Ticarcillin/clavulanate
Table 29: Efficacy of Ticarcillin/clavulanate in Patients with cIAIs1
Table 30: Product Profile-Aztreonam
Table 31: Efficacy of Aztreonam
Table 32: Safety of Aztreonam in Patients with Bacterial Infections
Table 33: Product Profile-Doribax
Table 34: Efficacy of Doribax in Patients with cIAIs
Table 35: Efficacy of Doribax in Patients with cUTIs
Table 36: Safety of Doribax
Table 37: Product Profile-Invanz
Table 38: Efficacy of Invanz in Patients with cIAIs
Table 39: Efficacy of Invanz in Patients with cUTIs
Table 40: Safety of Invanz
Table 41: Most Frequently Used Cephalosporins in HAIs
Table 42: Product Profile-Levofloxacin
Table 43: Efficacy of Levaquin in Patients with Nosocomial Pneumonia
Table 44: Efficacy of Levaquin in Patients with cUTIs and Acute Pyelonephritis
Table 45: Safety of Levofloxacin in Patients with Bacterial Infections
Table 46: Product Profile-Ciprofloxacin
Table 47: Efficacy of Ciprofloxacin in Patients with cUTIs
Table 48: Safety of Ciprofloxacin in Patients with Bacterial Infections
Table 49: Product Profile-Moxifloxacin
Table 50: Efficacy of Moxifloxacin in Patients with cIAIs
Table 51: Safety of Moxifloxacin in Patients with Bacterial Infections
Table 52: Aminoglycoside Susceptibility of Strains Isolated from Hospitalized Patients with Pneumonia* 1
Table 53: Product Profile-Amikacin 1
Table 54: Efficacy of Amikacin in Patients with Bacterial Infections 1
Table 55: Safety of Amikacin in Patients with Bacterial Infections 15
Table 56: Product Profile-Gentamicin 154
Table 57: Efficacy of Gentamicin in Patients with Bacterial Infections 155
Table 58: Safety of Gentamicin in Patients with Bacterial Infections 155
Table 59: Product Profile-Tobramycin 156
Table 60: Product Profile-Tygacil
Table 61: Efficacy of Tygacil in Patients with cIAIs
Table 62: Efficacy of Tygacil in Patients with HAP/VAP 160
Table 63: Safety of Tygacil 1
Table64: Infrequently Used Antibiotics for the Treatment of HAI Caused by Gram-Negative Bacteria 1
Table 65: Key Late-Stage Pipeline Agents for HAIs Caused by Gram-Negative Bacteria, 2017 1
Table 66: Product Profile-Avibactam/Aztreonam 1
Table 67: Pathogen Susceptibility to Avibactam/Aztreonam 1
Table 68: Avibactam/Aztreonam SWOT Analysis, 2017 1
Table 69: Product Profile-Meropenem/Vaborbactam 1
Table 70: Meropenem/Vaborbactam-Phase III Clinical Trials 1
Table 71: Meropenem/Vaborbactam SWOT Analysis, 2017 200
Table 72: Product Profile-Relebactam/Imipenem/Cilastin 202
Table 73: Relebactam/Imipenem/Cilastin-Phase II and Phase III Clinical Trials 204
Table 74: Relebactam/Imipenem/Cilastin-Phase II Results (cIAI/cUTI) 205
Table 75: Safety of Relebactam/Imipenem/Cilastin 206
Table 76: Relebactam/Imipenem/Cilastin SWOT Analysis, 2017 207
Table 77: Product Profile-Cefiderocol
Table 78: Cefiderocol-Phase II and Phase III Clinical Trials 2
Table 79: Cefiderocol SWOT Analysis, 2017 2
Table 80: Product Profile-Eravacycline 2
Table 81: Eravacycline-Phase II and Phase III Clinical Trials 2
Table 82: Eravacycline-Phase III Clinical Trials Results for cIAIs 2
Table 83: Eravacycline-Safety Profile 2
Table 84: Eravacycline SWOT Analysis, 2017 2
Table : Product Profile-Finafloxacin 2
Table : Finafloxacin-Phase II Efficacy for Patients with UTI 2
Table : Finafloxacin SWOT Analysis, 2017 2
Table : Product Profile-Plazomicin 2
Table : Plazomicin-Clinical Trials 2
Table : Plazomicin-Results from Phase III Trial with cUTI Patients 2
Table : Plazomicin-Results from Phase III Trial with cUTI Patients 2
Table : Plazomicin-Safety Results from Phase III Trials 2
Table : Eravacycline SWOT Analysis, 2017 2
Table : Product Profile-Panobacumab 2
Table : Aerumab-Phase II Clinical Trials 2
Table : Aerumab-Phase II Clinical Trial Results 2
Table : Aerumab SWOT Analysis, 2017 2
Table : Product Profile-MEDI32 2
Table : MEDI32-Phase II Clinical Trials 2
Table : MEDI32-Safety Data
Table : MEDI32 SWOT Analysis, 2017
Table : Drugs in Development for HAI Caused by Gram-Negative Bacteria, 2017 2
Table : Key Companies in the HAIs Marketplace in the 7MM, 2017 2
Table : Pfizer's HAI Portfolio Assessment, 2017
Table : Merck& Co's Gram-Negative HAIs Portfolio Assessment, 2017
Table : The Medicines Company's Gram-Negative HAIs Portfolio Assessment, 2017 2
Table : Shionogi's Gram-Negative HAIs Portfolio Assessment, 2017 2
Table : Tetraphase Pharmaceutical's Gram-Negative HAIs Portfolio Assessment, 2017 25
Table : MerLion Pharmaceutical's Gram-Negative HAIs Portfolio Assessment, 2017 254
Table : Achaogen's Gram-Negative HAIs Portfolio Assessment, 2017 255
Table : Aridis' HAI Portfolio Assessment, 2017 256
Table : MedImmune's Gram-Negative HAI Portfolio Assessment, 2017
Table : Allergan's Gram-Negative HAI Portfolio Assessment, 2017
Table : Global (7MM) Sales Forecasts (USD M) for Therapeutics Against HAIs Caused by Gram-Negative Bacteria, 2016-2026 26
Table : HAIs Caused by Gram-Negative Bacteria-Global Drivers and Barriers, 2016-2026 2
Table : Sales Forecasts (USD M) for Therapeutics Against HAIs Caused by Gram-Negative Bacteria in the US, 2016-2026
Table : Key Events Impacting Sales for HAIs Caused by Gram-Negative Bacteria in the US, 2016-2026 2
Table : HAIs caused by Gram-Negative Bacteria-US Drivers and Barriers, 2016-2026 2
Table : 5EU Sales Forecasts (USD M) for Therapeutics Against HAIs Caused by Gram-Negative Bacteria, 2016-2026 2
Table : Key Events Impacting Sales for HAIs Caused by Gram-Negative Bacteria in the 5EU, 2016-2026 27
Table : HAIs Caused by Gram-Negative Bacteria-5EU Drivers and Barriers, 2016-2026 27
Table 122: Sales Forecasts (USD M) for Therapeutics Against HAIs Caused by Gram-Negative Bacteria in Japan, 2016-2026 281
Table 123: Key Events Impacting Sales for HAIs Caused by Gram-Negative Bacteria in Japan, 2016-2026 284
Table : HAIs Caused by Gram-Negative Bacteria-Japan Drivers and Barriers, 2016-2026 2
Table : Key Historical and Projected Launch Dates for HAI Caused by Gram-negative Bacteria Across the 7MM
Table : Projected Patent Expiry Dates for HAI Caused by Gram-negative Bacteria Across the 7MM
Table 127: Key Assumptions for Avycaz
Table : Key Assumptions for Zerbaxa 345
Table : Key Assumptions for Piperacillin/tazobactam 345
Table 130: Key Assumptions for Ticarcillin/tazobactam 346
Table : Key Assumptions for Aztreonam 347
Table 132: Key Assumptions for Doribax 34
Table 133: Key Assumptions for Invanz 34
Table 134: Key Assumptions for Meropenem 34
Table : Key Assumptions for Imipenem 34
Table 136: Key Assumptions for Cefoxitin
Table : Key Assumptions for Cefotaxime
Table : Key Assumptions for Ceftriaxone
Table : Key Assumptions for Cefoperazone 35
Table 140: Key Assumptions for Ceftazidime 354
Table : Key Assumptions for Cefepime 355
Table : Key Assumptions for Zevtera 356
Table : Key Assumptions for Levofloxacin 357
Table : Key Assumptions for Ciprofloxacin 35
Table : Key Assumptions for Moxifloxacin 35
Table 146: Key Assumptions for Amikacin 360
Table 147: Key Assumptions for Gentamicin
Table 148: Key Assumptions for Tobramycin 362
Table 149: Key Assumptions for Polymyxin B 36
Table 150: Key Assumptions for Polymyxin E 364
Table 151: Key Assumptions for Tygacil 365
Table 152: Key Assumptions for Other Antibiotics 366
Table 153: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.